

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-55. (Canceled)

56. (Currently amended) An array [[for]] to aid in diagnosing ulcerative colitis (UC) in a subject comprising:

(a) [[a]] nucleic acid probes for determining an expression level of a melanoma growth stimulatory activity (GRO1) gene product (SEQ ID NO:2) [[or]] and a SLC26A2 gene product (SEQ ID NO:176) in a sample from said subject; and

(b) a substrate to which said nucleic acid probes [[its]] are bound, wherein said nucleic acid probes are 12-40 nucleotides in length, complementary to said GRO1 or SLC26A2 gene product, and hybridize under high stringency conditions to said GRO1 or SLC26A2 gene product, and

wherein an increase in the expression level of said GRO1 gene product or a decrease in the expression level of said SLC26A2 gene product in said sample relative to the expression level of the same gene product in normal tissue indicates that said subject has UC.

57. (Previously presented) The array of claim 56, wherein the expression level of said GRO1 gene product in said sample is increased relative to the expression level of the same gene product in normal tissue by at least a factor of two.

58. (Withdrawn) The array of claim 56, wherein the expression level of said SLC26A2 gene product in said sample is decreased relative to the expression level of the same gene product in normal tissue by at least a factor of two.

59. (Previously presented) The array of claim 56, wherein said sample is a needle biopsy core, a surgical resection sample, a bowel sample, lymph node tissue, or serum.

60. (Canceled)

61. (Currently amended) The array of claim ~~[[60]]~~ 56, wherein said nucleic acid probes consist~~[[s]]~~ of a sequence that is complementary to 12-40 consecutive nucleotides of SEQ ID NO:2 or SEQ ID NO:176.

62. (Canceled)

63. (Canceled)

64. (Previously presented) The array of claim 56, wherein said substrate is selected from the group consisting of paper, a membrane, a filter, a chip, a pin, and glass.

65. (Currently amended) The array of claim 56, wherein said nucleic acid probes ~~[[is]]~~ are bound to said substrate by covalent bonds or hydrophobic interactions.

66. (Currently amended) The array of claim 56, wherein said nucleic acid probes ~~[[is]]~~ are spotted onto said substrate in a two-dimensional matrix or array.

67. (Currently amended) The array of claim 56, wherein said nucleic acid probes further comprise~~[[s]]~~ a detectable label.

68. (Previously presented) The array of claim 67, wherein said detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a chemiluminescent compound, an enzyme, and an enzyme co-factor.